ES2096915T3 - Derivado de 5-o-desosaminileritronolida a. - Google Patents

Derivado de 5-o-desosaminileritronolida a.

Info

Publication number
ES2096915T3
ES2096915T3 ES93909404T ES93909404T ES2096915T3 ES 2096915 T3 ES2096915 T3 ES 2096915T3 ES 93909404 T ES93909404 T ES 93909404T ES 93909404 T ES93909404 T ES 93909404T ES 2096915 T3 ES2096915 T3 ES 2096915T3
Authority
ES
Spain
Prior art keywords
derivative
general formula
desosaminileritronolida
formula
ieritronolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93909404T
Other languages
English (en)
Inventor
Toshifumi Asaka
Masato Kashimura
Yoko Misawa
Shigeo Morimoto
Katsuo Hatayama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2096915T3 publication Critical patent/ES2096915T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Amplifiers (AREA)
  • Control Of High-Frequency Heating Circuits (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

OBJETO: PROPORCIONAR UN NUEVO ANTIBIOTICO MACROLIDO QUE TIENE UNA POTENTE ACTIVIDAD ANTIBACTERIANA. CONSTITUCION: UN DERIVADO DE CARBAMATO TRICICLICO DE UN DERIVADO DE A IERITRONOLIDA O DO POR LA FORMULA GENERAL (I), Y UNA SAL DE ADICION ACIDA DEL MISMO FARMACEUTICAMENTE ACEPTABLE. EN LA FORMULA (I), EPRESENTA C1 UN INTERMEDIARIO REPRESENTADO POR LA FORMULA GENERAL (II), UTIL PARA PRODUCIR EL DERIVADO A DESOSAMINILERITRONOLIDA SUSTITUIDO
ES93909404T 1992-04-22 1993-04-21 Derivado de 5-o-desosaminileritronolida a. Expired - Lifetime ES2096915T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10149292 1992-04-22

Publications (1)

Publication Number Publication Date
ES2096915T3 true ES2096915T3 (es) 1997-03-16

Family

ID=14302174

Family Applications (2)

Application Number Title Priority Date Filing Date
ES93909403T Expired - Lifetime ES2087737T3 (es) 1992-04-22 1993-04-21 Un derivado 5-o-desosaminil-eritronoluro a.
ES93909404T Expired - Lifetime ES2096915T3 (es) 1992-04-22 1993-04-21 Derivado de 5-o-desosaminileritronolida a.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES93909403T Expired - Lifetime ES2087737T3 (es) 1992-04-22 1993-04-21 Un derivado 5-o-desosaminil-eritronoluro a.

Country Status (12)

Country Link
US (2) US5591837A (es)
EP (2) EP0638584B1 (es)
KR (2) KR100244729B1 (es)
AT (2) ATE135707T1 (es)
AU (2) AU661585B2 (es)
BR (1) BR1100235A (es)
CA (2) CA2118488C (es)
DE (2) DE69305987T2 (es)
DK (2) DK0638584T3 (es)
ES (2) ES2087737T3 (es)
GR (2) GR3019787T3 (es)
WO (2) WO1993021200A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739620B1 (fr) * 1995-10-09 1997-12-19 Roussel Uclaf Nouveaux derives de la 5-0-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
USRE38426E1 (en) * 1995-10-09 2004-02-10 Aventis Pharma S.A. 5-O-deosaminyl 6-O-methyl erythronolide A derivatives, preparation method therefor and use thereof for preparing biologically active materials
ATE259823T1 (de) * 1995-11-08 2004-03-15 Abbott Lab Tricyclische erythromycinderivate
US6274715B1 (en) * 1995-11-08 2001-08-14 Abbott Laboratories Tricyclic erythromycin derivatives
US5747466A (en) * 1995-11-08 1998-05-05 Abbott Laboratories 3-deoxy-3-descladinose derivatives of erythromycins A and B
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
DE69733422T2 (de) * 1996-09-04 2006-05-04 Abbott Laboratories, Abbott Park 6-0-substituierte ketoliden mit antibakteriellen wirkung
UA51730C2 (uk) * 1996-09-04 2002-12-16 Ебботт Лабораторіз 6-o-заміщені кетоліди з антибактеріальною активністю, спосіб їх одержання (варіанти), фармацевтична композиція та спосіб регулювання бактеріальної інфекції у ссавців
US6191118B1 (en) * 1996-11-27 2001-02-20 Taisho Pharmaceutical Co., Ltd. Erythromycin A derivatives
FR2757168B1 (fr) * 1996-12-12 1999-06-11 Hoechst Marion Roussel Inc Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
AU4472897A (en) * 1997-03-10 1998-09-29 Taisho Pharmaceutical Co., Ltd. Erythromycin a derivatives
US6140479A (en) * 1997-03-24 2000-10-31 Taisho Pharmaceuticals Co., Ltd. Erythromycin a derivatives
WO1998051696A1 (en) * 1997-05-09 1998-11-19 Pfizer Products Inc. Erythromycin derivatives
US5922683A (en) * 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
SI0984975T1 (en) * 1997-05-29 2004-02-29 Abbott Laboratories Multicyclic erythromycin derivatives
US5780605A (en) * 1997-09-08 1998-07-14 Abbott Laboratories 6,9-bridged erythromycin derivatives
US5780604A (en) * 1997-09-26 1998-07-14 Abbott Laboratories 11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides
PA8461401A1 (es) * 1997-10-29 2000-05-24 Pfizer Prod Inc Derivados de eritromicina triciclicos
HN1998000159A (es) * 1997-10-29 1999-02-09 Monsanto Co Derivados de 9- amino - 3 ceto eritromicina
US6124269A (en) * 1997-10-29 2000-09-26 Abbott Laboratories 2-Halo-6-O-substituted ketolide derivatives
CO4990960A1 (es) * 1997-10-29 2000-12-26 Abbott Lab Derivados de cetolidos 2-halo-6-o sustituidos
FR2777282B1 (fr) * 1998-04-08 2001-04-20 Hoechst Marion Roussel Inc Nouveaux derives de la 2-fluoro 3-de((2,6-dideoxy 3-c-methyl 3-0-methyl-alpha-l-ribohexopyranosyl) oxyl) 6-o-methyl 3-oxo erythromycine, leur procede de preparation et leur application a la synthese de principes actifs de medicaments
EP0952157B1 (en) * 1998-04-24 2003-06-18 Pfizer Products Inc. 9A, 11B-Dehydro derivatives of 9-oxime-3-keto-6-0-methylerythromycin
US6248719B1 (en) 1998-06-03 2001-06-19 Pfizer Inc Tricyclic 3-keto derivatives of 6-O-methylerthromycin
FR2784682B1 (fr) * 1998-10-15 2002-12-06 Hoechst Marion Roussel Inc Nouveaux derives 2-halogene de 5-0-desosaminylerythronolide a, leur procede de preparation et leur application comme medicaments
US6054435A (en) * 1999-03-19 2000-04-25 Abbott Laboratories 6-O-substituted macrolides having antibacterial activity
US6355620B1 (en) 1999-05-14 2002-03-12 Abbott Laboratories C-2 modified erythromycin derivatives
ID27331A (id) * 1999-09-29 2001-03-29 Pfizer Prod Inc Pembuatan antibiotik-antibiotik ketolida karbamat
US6569836B2 (en) 1999-12-02 2003-05-27 Abbott Laboratories 6-O-alkyl-2-nor-2-substituted ketolide derivatives
US6946446B2 (en) 2000-02-24 2005-09-20 Abbott Laboratories Anti-infective agents useful against multidrug-resistant strains of bacteria
EP1146051A3 (en) * 2000-04-10 2001-10-31 Pfizer Products Inc. Erythromycin A derivatives
US7135573B2 (en) * 2002-05-13 2006-11-14 Enanta Pharmaceuticals, Inc. Processes for the preparation of O-(6-Pyrazol-1-yl-pyridin-3-ylmethyl)-hydroxylamine
US7273853B2 (en) * 2002-05-13 2007-09-25 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
US6878691B2 (en) * 2002-05-13 2005-04-12 Enanta Pharmaceuticals, Inc. 6-11 bicyclic ketolide derivatives
US7129221B2 (en) * 2002-05-13 2006-10-31 Enanta Pharmaceuticals, Inc. 6,11-bicyclic erythromycin derivatives
US6764998B1 (en) 2003-06-18 2004-07-20 Enanta Pharmaceuticals, Inc. 6,11-4C-bicyclic 9a-azalide derivatives
US7064110B2 (en) * 2002-05-13 2006-06-20 Enanta Pharmaceuticals, Inc. 6-11 bicycle ketolide derivatives
US7910558B2 (en) * 2002-05-13 2011-03-22 Enanta Pharmaceuticals, Inc. Bridged macrocyclic compounds and processes for the preparation thereof
US6841664B2 (en) * 2002-07-25 2005-01-11 Enanra Pharmaceuticals, Inc. 6,11-4-carbon bridged ketolides
WO2005070918A1 (en) * 2002-05-13 2005-08-04 Enanta Pharmaceuticals, Inc. Process for the preparation of t-11 bicyclic erythromycin derivatives
US6753318B1 (en) * 2002-07-25 2004-06-22 Enanta Pharmaceuticals, Inc. 6,11-4-carbon bridged erythromycin derivatives
US6645941B1 (en) 2003-03-26 2003-11-11 Enanta Pharmaceuticals, Inc. 6,11-3C-bicyclic 9a-azalide derivatives
WO2005030227A1 (en) * 2003-09-23 2005-04-07 Enanta Pharmaceuticals, Inc. 9a, 11-3C-BICYCLIC 9a-AZALIDE DERIVATIVES
US7414030B2 (en) * 2004-01-07 2008-08-19 Enanta Pharmaceuticals, Inc. 6-11 Bicyclic erythromycin derivatives
WO2005070113A2 (en) * 2004-01-09 2005-08-04 Enanta Pharmaceuticals, Inc. 9n-substituted 6-11 bicyclic erythromycin derivatives
US7163906B2 (en) * 2004-11-04 2007-01-16 Chevron Phillips Chemical Company, Llp Organochromium/metallocene combination catalysts for producing bimodal resins
US7419962B2 (en) 2004-12-07 2008-09-02 Enanta Pharmaceuticals, Inc. 3,6-bicyclolides
US7229972B2 (en) 2004-12-07 2007-06-12 Enanta Pharmaceuticals, Inc. 3,6-Bicyclolides
WO2006065721A2 (en) 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. 11, 12-lactone bicyclolides
WO2006065743A2 (en) 2004-12-13 2006-06-22 Enanta Pharmaceuticals, Inc. Tetracylic bicyclolides
US7384922B2 (en) * 2005-05-04 2008-06-10 Enanta Pharmaceuticals, Inc. 6-11 bridged oxime erythromycin derivatives
RU2455308C2 (ru) 2006-05-01 2012-07-10 Тайсо Фармасьютикал Ко., Лтд. Макролидные производные
US20070298811A1 (en) * 2006-06-21 2007-12-27 Lockheed Martin Corporation System for predicting bandwidth capacity
WO2009006403A2 (en) * 2007-06-29 2009-01-08 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylase (hdac) inhibitors and methods of making and using thereof
US8871728B2 (en) 2007-06-29 2014-10-28 Georgia Tech Research Corporation Non-peptide macrocyclic histone deacetylese (HDAC) inhibitors and methods of making and using thereof
EP2203435B1 (en) * 2007-09-17 2018-07-18 Enanta Pharmaceuticals, Inc. 6, 11-bridged biaryl macrolides
US8273720B2 (en) * 2007-09-17 2012-09-25 Enanta Pharmaceuticals, Inc. 6,11-bicyclolides: bridged biaryl macrolide derivatives
US8354383B2 (en) * 2007-09-17 2013-01-15 Enanta Pharmaceuticals, Inc. 6,11-bridged biaryl macrolides
TW200946109A (en) * 2008-05-09 2009-11-16 Enanta Pharm Inc Anti-bacterial activity of 9-hydroxy derivatives 6, 11-bicyclolides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5175150A (en) * 1985-08-31 1992-12-29 Kitasato, Kenkyusho Erythromycin derivative
US4742049A (en) * 1986-06-04 1988-05-03 Abbott Laboratories Semisynthetic erythromycin antibiotics
IL99995A (en) * 1990-11-21 1997-11-20 Roussel Uclaf Erythromycin derivatives, their preparation and pharmaceutical compositions containing them
EP0559896B1 (en) * 1990-11-28 1997-08-27 Taisho Pharmaceutical Co. Ltd 6-o-methylerythromycin a derivative
US5523399A (en) * 1991-12-27 1996-06-04 Taisho Pharmaceutical Co., Ltd. 5-O-desosaminylerythronolide derivatives

Also Published As

Publication number Publication date
DE69301916D1 (de) 1996-04-25
EP0638585A1 (en) 1995-02-15
WO1993021199A1 (fr) 1993-10-28
BR1100235A (pt) 2002-04-30
US5631355A (en) 1997-05-20
EP0638584A1 (en) 1995-02-15
DE69305987T2 (de) 1997-03-06
DK0638584T3 (da) 1996-04-15
ATE135707T1 (de) 1996-04-15
AU4022393A (en) 1993-11-18
EP0638584A4 (en) 1994-12-23
KR100244729B1 (ko) 2000-02-15
ES2087737T3 (es) 1996-07-16
EP0638585A4 (en) 1995-04-19
EP0638585B1 (en) 1996-11-13
KR950700921A (ko) 1995-02-20
DE69305987D1 (de) 1996-12-19
AU661585B2 (en) 1995-07-27
DK0638585T3 (da) 1996-12-02
WO1993021200A1 (en) 1993-10-28
DE69301916T2 (de) 1996-08-08
CA2118489C (en) 1999-07-13
KR950700920A (ko) 1995-02-20
KR0166996B1 (ko) 1999-01-15
CA2118488C (en) 2002-11-05
AU662420B2 (en) 1995-08-31
ATE145212T1 (de) 1996-11-15
GR3019787T3 (en) 1996-07-31
CA2118488A1 (en) 1993-10-23
CA2118489A1 (en) 1993-10-23
AU4022293A (en) 1993-11-18
EP0638584B1 (en) 1996-03-20
GR3021992T3 (en) 1997-03-31
US5591837A (en) 1997-01-07

Similar Documents

Publication Publication Date Title
ES2096915T3 (es) Derivado de 5-o-desosaminileritronolida a.
ATE148130T1 (de) Typ-iv-dipeptidyl-aminopeptidase-inhibitoren
ES2191292T3 (es) Compuestos antivirales poliaromaticos.
YU51095A (sh) Benzokazolil - i benzotiazolil-oksazo lidinoni
MX9301129A (es) Nuevas ciclosporinas y composiciones farmaceuticas que las contienen.
EP0695171A1 (en) GONADOTROPINE CONTAINING FREEZER DRIED DROPS
CO4950529A1 (es) Dihidropirimidinas y productos que las contienen
ECSP941111A (es) Nuevas sulfonilaminopirimidinas,
ES2051700T3 (es) Un proceso para la preparacion de un compuesto beta-lactama.
YU1097A (sh) 2-okso i 2-tio-1,2-dihidrohinolinil-oksazolidinoni
NZ334848A (en) Use of 1-hydroxy-2-pyridones for the treatment of skin diseases caused by fungi and bacteria
BR9302433A (pt) Composto,composicao farmaceutica,processos para tratar infeccoes virais e neoplasmas
ES2117132T3 (es) Sales de desferrioxamina-b y su uso como queladores de hierro eficaces por via oral.
ES472284A1 (es) Procedimiento para la preparacion de 6-deoxineamina
ES2072386T3 (es) Derivados del penciclovir para el tratamiento de las infecciones de hepatitis-b.
ES2086442T3 (es) Derivados de fluoroetilcamptotecina.
ES2122085T3 (es) Combinacion antibiotica.
ES2101747T3 (es) Penciclovir y famciclovir y derivados de guanina relacionados para el tratamiento de infecciones por vih-1.
ES2191908T3 (es) 4-aminopirrol(3,2-d)pirimidinas como antagonistas del receptor del neuropeptido.
ES2118248T3 (es) Esteres y amidas de 9-cloro-prostaglandina y su empleo para preparar medicamentos.
MX9300638A (es) Derivados del acido aminobenzoico.
ES2110405T3 (es) Un nuevo antibiotico, desoximulundocandina, un procedimiento para su produccion y su uso como medicamento.
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
ES2136659T3 (es) Procedimiento de secado por pulverizacion de aminoguanidina.
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 638585

Country of ref document: ES